Results 171 to 180 of about 40,704 (273)

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source

MOLECULAR-GENETIC APPROACH FOR OPTIMIZATION OF MODERN ANTIAGGREGANT THERAPY

Acta Biomedica Scientifica, 2012
The targets of application of antiaggregant therapy by clopidogrel and the factors that influence its outcome were presented, in this review. Special attention was given to the application of personalized, approach for the optimization of clopidogrel ...
N. YU. Knauer, G. I. Lifshits
doaj  

Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study [PDF]

ObjectivesThis study sought to determine the impact of gene polymorphisms on platelet reactivity (PR) after clopidogrel 150 mg/day in patients treated with percutaneous coronary intervention (PCI).BackgroundAlthough high maintenance-dose (MD) clopidogrel
Hwang, Jin-Yong, Hwang, Seok-Jae, Jeong, Young-Hoon, Kang, Min-Kyung, Kim, In-Suk, Koh, Jin-Sin, Kwak, Choong Hwan, Park, Yongwhi   +7 more
core   +1 more source

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development

Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1718-1731, June 2025.
Conducting clinical studies on drug–drug‐gene interactions (DDGIs) and extrapolating the findings into clinical dose recommendations is challenging due to the high complexity of these interactions. Here, physiologically‐based pharmacokinetic (PBPK) modeling networks present a new avenue for exploring such complex scenarios, potentially informing ...
Simeon Rüdesheim, Helena Leonie Hanae Loer, Denise Feick, Fatima Zahra Marok, Laura Maria Fuhr, Dominik Selzer, Donato Teutonico, Annika R. P. Schneider, Juri Solodenko, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr   +14 more
wiley   +1 more source

A Phenotyping Tool for Seven Cytochrome P450 Enzymes and Two Transporters: Application to Examine the Effects of Clopidogrel and Gemfibrozil

Clinical Pharmacology &Therapeutics, Volume 117, Issue 6, Page 1732-1742, June 2025.
Clinical cocktails for cytochrome P450 (CYP) phenotyping lack a marker for CYP2C8. We aimed to combine the CYP2C8 index drug repaglinide with the Geneva cocktail (caffeine/CYP1A2, bupropion/CYP2B6, flurbiprofen/CYP2C9, omeprazole/CYP2C19, dextromethorphan/CYP2D6, and midazolam/CYP3A4). We also included endogenous organic anion transporting polypeptide (
Laura Aurinsalo, Outi Lapatto‐Reiniluoto, Mika Kurkela, Mikko Neuvonen, Johanna I. Kiiski, Mikko Niemi, Aleksi Tornio, Janne T. Backman   +7 more
wiley   +1 more source

Regulatory Effects of Betonica macrantha Extract, Known as Mountain Tea, on miRNA Expression and Its Pharmacokinetic Properties

Food Science &Nutrition, Volume 13, Issue 6, June 2025.
Betonica macrantha methanol extract exhibited anticancer activity against MDA‐MB‐231 breast cancer cells (IC50: 0.8 mg/mL), upregulating miR‐19, miR‐20a, miR‐126, and miR‐200c. GC–MS and HPLC analyses identified key bioactive compounds, including α‐pinene, caryophyllene, and catechin, which showed favorable pharmacokinetics and target interactions ...
Muhammed Emin Sarı, Emine Incilay Torunoğlu, Zeynep Betül Sarı, Erdi Can Aytar, Abidin Gümrükçüoğlu, Alper Durmaz, Gamze Demirel   +6 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA‐Labeled Dosing Frequency of RHB‐105 Low‐Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication

The Journal of Clinical Pharmacology, Volume 65, Issue 6, Page 779-786, June 2025.
Abstract Patient adherence is vital for Helicobacter pylori eradication. Simplifying therapy dosing schedules may promote patient adherence, enhance treatment success rates, and help mitigate the development of antibiotic resistance. We aimed to assess plasma and intragastric rifabutin, amoxicillin, and omeprazole concentrations comparing two dosing ...
Nimish Vakil, Colin W. Howden, Shailja C. Shah, Kuan‐Fu Chen, Elliot Offman, June S. Almenoff, Kely L. Sheldon   +6 more
wiley   +1 more source

Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach

Heliyon
Introduction: CYP2C19 is a highly polymorphic gene responsible for metabolizing commonly used drugs. CYP2C19*2,*3 (loss of activity alleles) and *17 (increased activity allele) are the principal alleles included in clinical guidelines, however their ...
Alba Alonso Llorente, Josefa Salgado Garrido, Óscar Teijido Hermida, Fabricio González Andrade, Alberto Valiente Martín, Ana Julia Fanlo Villacampa, Jorge Vicente Romero   +6 more
doaj  

Assessments of CYP‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such as statins.
Hang Yang, Shuanghu Wang, Quan Zhou, Peiwu Geng, Zebei Lu, Qinrong Lin, Chunhong Chen, Yunfang Zhou, Jianping Cai, Dapeng Dai   +9 more
wiley   +1 more source

Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype

Journal of Pharmacological Sciences, 2019
Polymorphisms of cytochrome P450 (CYP) enzymes can affect enzymatic activity, drug metabolism and drug interactions. Although the potential for drug interactions is especially important when co-administering drugs with strong inductive or inhibitory ...
Chiaki Kamiya, Naoki Inui, Akio Hakamata, Sachiko Miyakawa, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Keiichi Odagiri, Hiroshi Watanabe   +8 more
doaj